Long-term mortality in hypertensive patients with coronary artery disease: Results from the US cohort of the international verapamil (SR)/trandolapril study

Hypertension

Volumn 68, Issue 5, 2016, Pages 1110-1114

  Elgendy, Islam Y ^a   Bavry, Anthony A ^a,c   Gong, Yan ^b   Handberg, Eileen M ^d   Cooper Dehoff, Rhonda M ^a,b   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE

Author keywords

adult; blood pressure; coronary artery disease; hypertension; mortality

Indexed keywords

TRANDOLAPRIL PLUS VERAPAMIL; INDOLE DERIVATIVE; TRANDOLAPRIL; VERAPAMIL;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GROUPS BY AGE; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES; AGED; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; INTERNATIONAL COOPERATION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL RATE; SYSTOLE; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE DETERMINATION; CAUSE OF DEATH; COMORBIDITY; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INDOLES; INTERNATIONALITY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; SYSTOLE; TREATMENT OUTCOME; UNITED STATES; VERAPAMIL;

EID: 84987596924     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07854     Document Type: Article

References (22)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A Report From the American Heart Association. Circulation. 2016;133:447-454.
2. Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435-e470. doi: 10.1161/CIR.0000000000000207.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. doi: 10.1093/eurheartj/eht151.
5. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15. doi: 10.1097/HJH.0000000000000065.
6. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.
7. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32:1228-1237.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816. doi: 10.1001/jama.290.21.2805.
9. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-68. doi: 10.1001/jama.2010.884.
10. Williams BC, Demitrack LB, Fries BE. The accuracy of the National Death Index when personal identifiers other than Social Security number are used. Am J Public Health. 1992;82:1145-1147.
11. Zoungas S, Chalmers J, Neal B, et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392-1406. doi: 10.1056/NEJMoa1407963.
12. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32:2525-2532. doi: 10.1093/eurheartj/ehr333.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589. doi: 10.1056/NEJMoa0806470.
14. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-2206. doi: 10.1056/NEJMoa1414266.
15. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503. doi: 10.7326/M13-2981.
16. Dong C, Della-Morte D, Rundek T, Wright CB, Elkind MS, Sacco RL. Evidence to maintain the systolic blood pressure treatment threshold at 140 mm Hg for stroke prevention: The Northern Manhattan Study. Hypertension. 2016;67:520-526. doi: 10.1161/HYPERTENSIONAHA.115.06857.
17. Cushman WC. Long-term cardiovascular effects of 4.9 years of intensive blood pressure control in type 2 diabetes mellitus: The Action to Control Cardiovascular Risk in Diabetes Follow-On Blood Pressure Study (ACCORDION). Presented at the American Heart Association Annual Scientific Sessions. November, 2015. Orlando, FL.
18. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension. 2016;67:808-812. doi: 10.1161/ HYPERTENSIONAHA.116.07257.
19. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. doi: 10.1016/S0140-6736(15)01225-8.
20. Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64:784-793. doi: 10.1016/j.jacc.2014.05.044.
21. Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25:83-92. doi: 10.3109/08037051.2015.1106750.
22. Meredith PA, Lloyd SM, Ford I, Elliott HL. Importance of sustained and "tight" blood pressure control in patients with high cardiovascular risk. Blood Press. 2016;25:74-82. doi: 10.3109/08037051.2015.1127528.